d-nome funding: Synthetic biology startup D-nome raises $1.5M in funding from Ankur Capital, Campus Fund

Synthetic biology startup D-Nome has raised $1.5 million in seed funding from Ankur Capital, Campus Fund, and other investors.

D-Nome intends to democratize molecular diagnostics using deviceless PCR technology.

Started in July 2021 by PhD students – Divya Sriram and Sujoy Deb – from the Center for Cellular and Molecular Biology in Telanaga, the startup is focused on building rapid point-of-care diagnostics for human infectious diseases and other applications using genomics and synthetic biology.

Our mission is to bridge the testing gap and enable personalized medicine at scale, which has not been successful due to a lack of accurate and scalable diagnostic tools. We hope to make a significant social and economic impact for developing countries and pave the way for the next generation of healthcare that relies heavily on genomics,”

Currently, there are three main methods of testing – routine culture which is time consuming and requires infrastructure, rapid antigen/antibody tests but lacks accuracy, and real-time PCR/PCR (RT-PCR) tests which are the gold standard for accuracy but are expensive and need to skilled labour.

Stay up to date with important tech and startup news. Subscribe to our daily newsletter for the latest must-read tech news, delivered straight to your inbox.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *